The tumor-targeting system, which will use human autoimmune antibodies, is expected to enhance the safety and effectiveness of current cancer drugs by improving localization at the tumor site.
The Children’s Hospital Los Angeles Department of Pathology’s Center for Personalized Medicine director Timothy Triche said that NanoSmart has leveraged a naturally occurring human antibody to target the nanoparticles to the tumor, which if successful should facilitate rapid approval from the FDA for use on Ewing’s sarcoma patients.
NanoSmart Pharmaceuticals president James Smith said that the strategic alliance will give the company access to vital preclinical and clinical resources.
"In addition to Dr. Triche’s expertise and guidance, we look forward to initial characterization and testing of NanoSmart’s formulations in the unique model of metastatic Ewing’s Sarcoma at Children’s Hospital," Smith said.